Novo Nordisk Share Price Already Reflects Plenty of Pessimism

Dow Jones08-28 18:39

1039 GMT - Novo Nordisk has faced immense pricing and competitive pressures, but the share price has baked in more than its fair share of pessimism, AlphaValue analyst Abhishek Raval writes. Oral weight-loss options are likely to be the key vehicles of market expansion, and the Danish drug maker still maintains a massive lead with its Wegovy pill versus Eli Lilly's Foundayo, he says. Novo Nordisk's CagriSema, a next generation obesity/diabetes injection, is expected to launch in 2027, and potential game changer Zenagamtide, an obesity/diabetes drug in both pill and injection form, could launch in 2029. These should fortify Novo Nordisk's already dominant position in the coming years, Raval says. AlphaValue retains its buy rating on the stock and lifts its target price to 466 Danish kroner from 458 kroner. Shares rise 0.7% to 297.20 kroner.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2662006493?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-28 18:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662006493","market":"other","top_or_hot":-1,"title":"Novo Nordisk Share Price Already Reflects Plenty of Pessimism","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>1039 GMT - Novo Nordisk has faced immense pricing and competitive pressures, but the share price has baked in more than its fair share of pessimism, AlphaValue analyst Abhishek Raval writes. Oral weight-loss options are likely to be the key vehicles of market expansion, and the Danish drug maker still maintains a massive lead with its Wegovy pill versus Eli Lilly's Foundayo, he says. Novo Nordisk's CagriSema, a next generation obesity/diabetes injection, is expected to launch in 2027, and potential game changer Zenagamtide, an obesity/diabetes drug in both pill and injection form, could launch in 2029. These should fortify Novo Nordisk's already dominant position in the coming years, Raval says. AlphaValue retains its buy rating on the stock and lifts its target price to 466 Danish kroner from 458 kroner. Shares rise 0.7% to 297.20 kroner.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Share Price Already Reflects Plenty of Pessimism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Share Price Already Reflects Plenty of Pessimism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-08-28 18:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>1039 GMT - Novo Nordisk has faced immense pricing and competitive pressures, but the share price has baked in more than its fair share of pessimism, AlphaValue analyst Abhishek Raval writes. Oral weight-loss options are likely to be the key vehicles of market expansion, and the Danish drug maker still maintains a massive lead with its Wegovy pill versus Eli Lilly's Foundayo, he says. Novo Nordisk's CagriSema, a next generation obesity/diabetes injection, is expected to launch in 2027, and potential game changer Zenagamtide, an obesity/diabetes drug in both pill and injection form, could launch in 2029. These should fortify Novo Nordisk's already dominant position in the coming years, Raval says. AlphaValue retains its buy rating on the stock and lifts its target price to 466 Danish kroner from 458 kroner. Shares rise 0.7% to 297.20 kroner.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVOX","symbol_name":"2倍做多NVO ETF-Defiance","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2662006493","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2662006493","pubTimestamp":1787913540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1039 GMT - Novo Nordisk has faced immense pricing and competitive pressures, but the share price has baked in more than its fair share of pessimism, AlphaValue analyst Abhishek Raval writes. Oral weight-loss options are likely to be the key vehicles of market expansion, and the Danish drug maker still maintains a massive lead with its Wegovy pill versus Eli Lilly's Foundayo, he says. Novo Nordisk's CagriSema, a next generation obesity/diabetes injection, is expected to launch in 2027, and potential game changer Zenagamtide, an obesity/diabetes drug in both pill and injection form, could launch in 2029. These should fortify Novo Nordisk's already dominant position in the coming years, Raval says. AlphaValue retains its buy rating on the stock and lifts its target price to 466 Danish kroner from 458 kroner. Shares rise 0.7% to 297.20 kroner.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVOX":"2倍做多NVO ETF-Defiance","BK4588":"碎股","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","PPH":"VanEck Pharmaceutical ETF","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","NVOC":"Corgi NVO 2x Daily ETF","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4532":"文艺复兴科技持仓","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4599":"减肥药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","NVO":"诺和诺德","BK4007":"制药","OZEM":"Roundhill GLP-1 & Weight Loss ETF"},"translate_title":"诺和诺德股价已经反映出大量悲观情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"THNR":0.6,"PPH":0.6,"NVOC":0.6,"OZEM":0.6,"NVOH":0.6,"NVOX":0.6,"NVO":1.97},"content_text":"1039 GMT - Novo Nordisk has faced immense pricing and competitive pressures, but the share price has baked in more than its fair share of pessimism, AlphaValue analyst Abhishek Raval writes. Oral weight-loss options are likely to be the key vehicles of market expansion, and the Danish drug maker still maintains a massive lead with its Wegovy pill versus Eli Lilly's Foundayo, he says. Novo Nordisk's CagriSema, a next generation obesity/diabetes injection, is expected to launch in 2027, and potential game changer Zenagamtide, an obesity/diabetes drug in both pill and injection form, could launch in 2029. These should fortify Novo Nordisk's already dominant position in the coming years, Raval says. AlphaValue retains its buy rating on the stock and lifts its target price to 466 Danish kroner from 458 kroner. Shares rise 0.7% to 297.20 kroner.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2662006493","isCrawlerRequest":true}